Late breaking news. Late breaking news 
Welcome to the era of the antibody.
Learn how IPA is leading its pharmaceutical partners into the era of the antibody.
Ranked #1 CRO
- Therapeutic
- Diagnostic
The HUB of intelligence with the best combination of people, platforms, and technologies to conquer deadly and debilitating diseases…
Wet lab + in silico specifically for antibody research
IPA builds on its reputation of excellence by delivering a new approach to AI that translates mass amounts of data into meaningful knowledge, to transform biotherapeutic science with unimaginable accuracy and efficiency…
In silico, in-house, incredible
The next evolution for the CRO and the new definition of end-to-end starts here. Learn about current applications for making better informed decisions faster, with the LENSai™ Product Portfolio from BioStrand (a subsidiary of IPA), like Immunogenicity Screening and more …
Events
Join us at an upcoming event. Contact us to connect or for more information.
AACR
Orlando USA | Apr. 14-19 | 2023
PEGS
Boston USA | May 15-19 | 2023
HUBX AB TX
Boston USA | May 22 | 2023
BIO International
Boston USA | Jun. 5-8 | 2023
AET Europe
Amsterdam EU | Jun. 6-8 | 2023
Resources and intelligence
Case Study
B cell Select® rabbit monoclonal antibodies – unmatched in the industry
Combining the high specificity and affinity of rabbit immune systems with the unbiased depth of our “Function-First” B cell Select workflow results in early identification of a superior panel of diagnostic antibodies.
Case Study
Generate sequence and functional diversity in transgenics
Generate a large panel of sequence-diverse, biologically relevant lead candidates that are specific to a small, processed protein (<3 kDa) with a difficult secondary structure using a transgenic animal model.
Webinar
Maximize the molecular quality of multi-pass membrane protein-targeting antibodies
Specificity testing in various assays can be complemented with affinity ranking of antibody panels or epitope mapping and binning, using BLI-based platforms. After hybridoma sequencing, we can clone, reformat, affinity mature, chimerize, or humanize your antibody before we produce the antibody recombinantly at a quality and quantity of your choice.